The diagnosis is made in the presence of the tetrad of altered mental status, muscle rigidity, autonomic dysfunction, and hyperthermia. A high index of suspicion leads clinicians to stop antipsychotic medications and institute supportive measures simultaneously with diagnostic evaluation, given the critical nature of this syndrome. This means that less severe cases (partial NMS, mild NMS) may be seen more often than the traditional severe and life-threatening presentations. This also makes the diagnosis more challenging, as many other conditions present with some or all of the features of NMS.
NMS remains a diagnosis of exclusion. A careful assessment, including physical exam and comprehensive tests, is required to exclude other potential causes.[3]Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185-202.
http://www.ncbi.nlm.nih.gov/pubmed/8093494?tool=bestpractice.com
[12]Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):265-9.
http://www.ncbi.nlm.nih.gov/pubmed/1354002?tool=bestpractice.com
History and physical exam
NMS is more likely to develop following initiation of antipsychotic therapy or an increase in the dose.[1]Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870-6.
http://www.ncbi.nlm.nih.gov/pubmed/17541044?tool=bestpractice.com
[5]Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998 Aug;155(8):1113-6.
http://www.ncbi.nlm.nih.gov/pubmed/9699705?tool=bestpractice.com
[28]Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry. 1997 Aug;154(8):1156-8.
http://www.ncbi.nlm.nih.gov/pubmed/9247408?tool=bestpractice.com
[39]Marshall PB, Mellman TA, Nguyen SX. Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine. Am J Psychiatry. 2008 Nov;165(11):1488-9.
http://www.ncbi.nlm.nih.gov/pubmed/18981078?tool=bestpractice.com
[40]Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008 Jul;69(7):1157-65.
http://www.ncbi.nlm.nih.gov/pubmed/18572981?tool=bestpractice.com
[41]Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998 Oct 15;44(8):748-54.
http://www.ncbi.nlm.nih.gov/pubmed/9798079?tool=bestpractice.com
[42]Viejo LF, Morales V, Punal P, et al. Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand. 2003 Jan;107(1):45-9.
http://www.ncbi.nlm.nih.gov/pubmed/12558541?tool=bestpractice.com
[43]Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989 Jun;146(6):717-25.
http://www.ncbi.nlm.nih.gov/pubmed/2567121?tool=bestpractice.com
All antipsychotic medications have been associated with NMS, presumably through their antagonism of dopamine D2 receptors.[24]Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981 Feb;31(2):132-7.
http://www.ncbi.nlm.nih.gov/pubmed/6110195?tool=bestpractice.com
Almost all patients develop symptoms within 30 days, with 16% developing symptoms within 24 hours after drug initiation and 66% within 1 week.[1]Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870-6.
http://www.ncbi.nlm.nih.gov/pubmed/17541044?tool=bestpractice.com
[35]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.
A prior episode of NMS is generally believed to significantly increase risk for subsequent episodes.
Often it can be difficult to differentiate an acute extrapyramidal reaction from NMS, especially if the prior episode is poorly described in the medical records.[3]Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185-202.
http://www.ncbi.nlm.nih.gov/pubmed/8093494?tool=bestpractice.com
[9]Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008 Sep;42(9):1290-7.
http://www.ncbi.nlm.nih.gov/pubmed/18628446?tool=bestpractice.com
[37]Mall GD, Hake L, Benjamin AB, et al. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report. J Clin Psychopharmacol. 2008 Oct;28(5):572-3.
http://www.ncbi.nlm.nih.gov/pubmed/18794658?tool=bestpractice.com
[41]Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998 Oct 15;44(8):748-54.
http://www.ncbi.nlm.nih.gov/pubmed/9798079?tool=bestpractice.com
[44]Groff K, Coffey BJ. Psychosis or atypical neuroleptic malignant syndrome in an adolescent? J Child Adolesc Psychopharmacol. 2008 Oct;18(5):529-32.
http://www.ncbi.nlm.nih.gov/pubmed/18928418?tool=bestpractice.com
It is useful to ask about a history of delirium, dementia, brain trauma, Wilson disease, or Parkinson disease because they appear to be associated with an increased risk for NMS in the context of antipsychotic use or abrupt withdrawal of dopaminergic drugs.[18]Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord. 2003 Apr:9 Suppl 1:S31-41.
http://www.ncbi.nlm.nih.gov/pubmed/12735913?tool=bestpractice.com
[28]Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry. 1997 Aug;154(8):1156-8.
http://www.ncbi.nlm.nih.gov/pubmed/9247408?tool=bestpractice.com
[29]Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989 Oct;46(10):914-8.
http://www.ncbi.nlm.nih.gov/pubmed/2572206?tool=bestpractice.com
Key clinical features to make a diagnosis include:
Altered mental status: characterized by confusion, delirium, or stupor.
Muscle rigidity: patients can develop muscle rigidity de novo, or worsening of preexisting muscle rigidity. It can be difficult to distinguish these two entities. Generalized rigidity (described as "lead pipe" in its most severe form and usually unresponsive to antiparkinsonian agents) is a cardinal feature. It may be associated with tremor, akinesia, dystonia, trismus, myoclonus, dysarthria, and dysphagia. Patients may have sialorrhea and rhabdomyolysis.[35]American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.
Hyperthermia: may occur simultaneously with diaphoresis or flushing, indicating a disruption of normal thermoregulatory coordination.
Autonomic disturbances: may include labile hypertension, tachycardia, tachypnea, urinary incontinence, and diaphoresis.
Tests
Laboratory investigations are essential to exclude other disorders or complications.
CBC: helpful to rule out sepsis, in conjunction with other clinical parameters.
Serum creatine kinase (CK) levels: patients with NMS may have significant increases in serum CK indicating muscle injury, with the risk of myoglobinuric acute kidney injury. Subsequent tests should be performed, often daily, until symptoms and laboratory abnormalities resolve.
Basic metabolic panel (BUN, creatinine): to evaluate the presence of complications such as acute kidney injury, and hydration status.
Myoglobin levels and urinalysis: myoglobinuria is a poor prognostic sign.
Urine/blood cultures and chest x-ray may be obtained to rule out sepsis and pneumonia.
CT/MRI brain scan: to rule out brain infection, mass, or bleed.[12]Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):265-9.
http://www.ncbi.nlm.nih.gov/pubmed/1354002?tool=bestpractice.com
Electroencephalogram: may be needed to rule out status epilepticus.
Toxicology screen: to exclude drug abuse/overdose/withdrawal.
Lumbar puncture: to rule out meningitis/encephalitis in patients with high fever, altered mental status, and rigidity.
More specific tests are guided by clinical circumstances.[12]Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):265-9.
http://www.ncbi.nlm.nih.gov/pubmed/1354002?tool=bestpractice.com
[45]Keshevan MS, Stecker J, Kambhampati RK. Creatine kinase elevations with clozapine. Br J Psychiatry. 1994 Jan;164(1):118-20.
http://www.ncbi.nlm.nih.gov/pubmed/7802755?tool=bestpractice.com